Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3898 | Tafenoquine Oral Tablet Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a 30 patient, Phase 1/2a multi-center pilot study to test the safety and to describe the preliminary efficacy of intravenous administration of allogenic human cord tissue mesenchymal stromal cells (hCT-MSC) as an investigational agent, under U.S. IND 19968 to patients with acute respiratory distress syndrome (ARDS) due to COVID-19 infection (COVID-ARDS). The key secondary endpoints are 28 day survival, an increase in PaO2/FiO2 ratio by 50% at 96 hours, days to hospital discharge to home or rehab, and number of days requiring mechanical ventilation. Patients will be eligible for treatment with 3 daily consecutive doses of hCT-MSC at 1 million cells/kg (max dose 100 million cells), 18-30 hours apart, if they have a confirmed diagnosis of COVID-19 and meet clinical and radiographic criteria for ARDS. Results from the first 10 patients will be compared with concurrent outcomes utilizing standard of care treatments in participating hospitals and in published reports in the medical literature. Results from the additional 20 patients will be combined with the first 10 and analyzed. The trial is relying on focused eligibility of the participants (patients with ARDS), single cohort with short trial time (4 weeks), and simple assessment of clinical outcome (survival, improvement of ARDS). This is a sequential design in the sense that after the first 10 patients are evaluated a decision will be made by the PIs and the Data Safety Monitoring Board whether to proceed with the exploratory randomized portion of the study.
Description: Incidence of infusion reactions measured by any one of the following: fever, anaphlyaxis, rash, hypertension, hypotension, tachycardia, nausea, vomiting, or any other new or worsening symptoms associated with the infusion.
Measure: Safety of the Investigational Product Time: 24 hoursDescription: Incidence of later reactions attributed to the investigational product as measured by any one of the following: rash, infection, allergic reaction, or any other symptoms associated with infusion of the investigational product.
Measure: Safety of the Investigational Product Time: 28 daysDescription: Formation of new anti-PRA antibodies as measured by an antibody screen test at 28 days post first infusion of the investigational product.
Measure: Safety of the Investigational Product Time: 28 daysDescription: Survival after 28 days after the first dose of MSCs
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: 28 daysDescription: Increase in PaO2/FiO2 ratio by 50%
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: 3 days after MSCsDescription: The number of days from hospitalization to discharge to home
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: 90 daysDescription: The number of ventilator free days
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: 90 daysDescription: A 50% decrease in opacities by CT chest one week post initiation of MSC therapy
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: 7 daysDescription: The number of days requiring oxygen support
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: 90 daysDescription: Changes in viral load after MSCs measured by routine PCR testing from baseline to 4 days, 7 days and 28 days after MSCs
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: baseline, day 4, day 7, and day 28Description: Number of patients able to be on the randomized portion of this study
Measure: Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs Time: 90 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports